<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment protocols for anal cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment protocols for anal cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment protocols for anal cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tim Brenner, PharmD, BCOP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shrina Duggal, PharmD, BCOP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jim Natale, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H801530553"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with anal cancer, both for primary treatment of locoregional disease, and for treatment of advanced disease. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with anal cancer. Additional regimens may be added over time, particularly as treatment for anal cancer evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with anal. Clinicians should refer to the individual disease-oriented topic review that discusses the use of these protocols in appropriate clinical situations. (See  <a class="medical medical_review" href="/z/d/html/2469.html" rel="external">"Clinical features and staging of anal cancer"</a>.)</p><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class="headingAnchor" id="H801530570"><span class="h1">REGIMENS</span></p><p class="headingAnchor" id="H21183931"><span class="h2">Initial therapy for locoregional disease</span></p><p class="headingAnchor" id="H801530598"><span class="h3">Mitomycin plus fluorouracil and RT</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef87178" href="/z/d/graphic/87178.html" rel="external">table 1</a>)</p><p class="headingAnchor" id="H3094809953"><span class="h3">Mitomycin plus capecitabine and RT</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef109549" href="/z/d/graphic/109549.html" rel="external">table 2</a>)</p><p class="headingAnchor" id="H2636132120"><span class="h3">Cisplatin plus fluorouracil and RT</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef87177" href="/z/d/graphic/87177.html" rel="external">table 3</a>)</p><p class="headingAnchor" id="H21183923"><span class="h2">Advanced disease</span></p><p class="headingAnchor" id="H21183950"><span class="h3">Cisplatin plus fluorouracil</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef89157" href="/z/d/graphic/89157.html" rel="external">table 4</a>)</p><p class="headingAnchor" id="H1862241005"><span class="h3">Docetaxel, cisplatin, and fluorouracil (DCF)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef130020" href="/z/d/graphic/130020.html" rel="external">table 5</a>)</p><p class="headingAnchor" id="H3148997769"><span class="h3">Weekly paclitaxel plus every-three-week carboplatin</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef130564" href="/z/d/graphic/130564.html" rel="external">table 6</a>)</p><p class="headingAnchor" id="H1612630098"><span class="h3">Every-three-week paclitaxel and carboplatin</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef122455" href="/z/d/graphic/122455.html" rel="external">table 7</a>)</p><p class="headingAnchor" id="H2010404846"><span class="h3">Modified DCF</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef130021" href="/z/d/graphic/130021.html" rel="external">table 8</a>)</p><p class="headingAnchor" id="H1458676495"><span class="h3">Nivolumab monotherapy</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 9</a>)</p><p class="headingAnchor" id="H3035987067"><span class="h3">Pembrolizumab monotherapy</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 10</a>)</p><p class="headingAnchor" id="H2794623218"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.</p></div><div id="topicVersionRevision">Topic 87181 Version 25.0</div></div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
